Review and evaluate bio-pharma assets for commercial development potential. Advise investors on drug science, validity of data, commercialization potential. Identify and surface early clinical stage assets (oncology, diagnostics, infectious disease) for structured financing programs (US and UK).

Evernear continues to build on a solid track record as an early and mid-stage human health technologies fund earned by its senior staff over decades of work in the field. By combining the insight of its seasoned development, clinical, market, business, and finance professionals with access to experienced scientific and clinical thought leaders, Evernear is able to identify unmet market needs, and pair these with transformative science and technology that address these. This marriage results in the sourcing and selection of high-science assets with the potential to deliver disruptive change to stakeholders (patients, physicians, and communities), and target returns for investors Show less

NSF funded post-doc, Department of Chemistry and Biochemistry/Department of Ecology and Evolutionary Biology

* 1) Taught undergraduate courses in Biochemical Ecology, Molecular Biology, Life-Sciences * 2) Led seminars (Graduate) in the application Biochemical and Proteomic Techniques to basic research * 2) Conducted Federally funded research (NSF, NIH) directed at discovering novel biochemical compounds used in chemical signaling (cell-cell to community-level production and response)